Lactic acid bacteria embedding structure with anti-allergy effect

Abstract

The utility model provides a lactic acid bacteria embedding structure with an anti-allergy effect. The lactic acid bacteria embedding structure comprises lactic acid bacteria particles, and the outer sides of the lactic acid bacteria particles are sequentially coated with an auxiliary effect layer, a storage-resistant layer, an acid and alkali resistant layer and an anti-collision layer; by arranging the auxiliary effect layer, the anti-allergy effect can be enhanced by cooperating with lactic acid bacteria after being eaten, and the effect of improving the anti-allergy effect of the lactic acid bacteria particles in the lactic acid bacteria embedding structure is achieved; the storage-resistant layer can enhance the stability of lactic acid bacteria and isolate air, humidity and high temperature, so that the storage life is prolonged; the acid and alkali resistant layer is used for enhancing the gastric acid and cholate resistant effect of lactic acid bacteria so as to ensure that thalli smoothly reach and colonize in intestinal tracts; the anti-collision layer can prevent the lactic acid bacteria from being pressed and damaged by the lactic acid bacteria powder due to the subsequent processing procedure or the conveying process of the lactic acid bacteria particles, so that the aim of increasing the survival rate of the lactic acid bacteria particles is fulfilled; through the arrangement and layout of each layer body, the effect of improving the anti-allergy effect of the lactic acid bacteria granules can be achieved, the activity of the lactic acid bacteria granules can be maintained, and the storage life is prolonged.

Description

Technical Field

[0001] The present application relates to the field of oral granules, and in particular to a lactic acid bacteria embedding structure with anti-allergic effects. Background Art

[0002] Allergy refers to an inappropriate immune response of the body to foreign substances (allergens). Asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, eczema, food allergies, etc., all fall into this category. Many allergic diseases are caused by an imbalance in the immune response between Th1 cells and Th2 cells, and the response to allergens is more biased towards the immune response of Th2 cells.

[0003] Studies have shown that lactobacillus has anti-allergic effects. More and more people are taking lactobacillus for anti-allergic treatment. In order to ensure the effectiveness of lactobacillus, it is necessary to ensure the high activity of lactobacillus. In the prior art, a layered particle structure is used.

[0004] For example, in the prior art, the application number of "Oral microparticles for maintaining high activity and stability of lactic acid bacteria" is 2017211301162, which includes a lactic acid bacteria particle, an anti-dehydration layer coated on the outside of the lactic acid bacteria particle, an anti-damage layer coated on the outside of the anti-dehydration layer, an antioxidant layer coated on the outside of the anti-damage layer, an oligosaccharide layer coated on the outside of the antioxidant layer, and a polysaccharide layer coated on the outside of the oligosaccharide layer. In this application, a multi-level embedding structure is used to isolate external moisture, air and high temperature, so that the lactobacillus particles have high survival rate, activity and stability, and can reach the user's intestines to be absorbed, so as to improve their biological absorption and utilization rate; however, the application cannot achieve the effect of acid and alkali resistance, thereby failing to ensure that the bacteria can smoothly reach and colonize in the intestines, and the application cannot prevent the lactic acid bacteria particles from being compressed and damaged by bacterial powder during the subsequent processing steps or transportation process, thereby reducing the survival rate of the lactic acid bacteria particles.

[0005] Therefore, it is necessary to provide a new technical solution to solve the above technical problems. Utility Model Content

[0006] The present application provides a lactic acid bacteria embedding structure with anti-allergic effect, comprising lactic acid bacteria particles, wherein the outer side of the lactic acid bacteria particles is coated with an auxiliary efficacy layer, the outer side of the auxiliary efficacy layer is coated with a storage-resistant layer, the outer side of the storage-resistant layer is coated with an acid- and alkali-resistant layer, and the outer side of the acid- and alkali-resistant layer is coated with an anti-collision layer.

[0007] As a preferred solution, the auxiliary efficacy layer uses one of docosahexaenoic acid, soybean peptide, lecithin, yeast extract, β-carotene, and conjugated linoleic acid.

[0008] As a preferred solution, the acid-alkali resistant layer is made of corn gum or gum arabic.

[0009] As a preferred solution, the anti-collision layer is made of one of amylose, microcrystalline cellulose, sorbitol, resistant dextrin, oat fiber, citrus fiber and inulin fiber.

[0010] As a preferred solution, the lactic acid bacteria particles, the auxiliary functional layer, the storage-resistant layer, the acid-alkali-resistant layer, and the anti-collision layer adopt a triangular structure.

[0011] In the present application, an auxiliary functional layer is set to ensure that after consumption, it can cooperate with lactic acid bacteria to enhance the anti-allergic effect, thereby achieving the effect of improving the anti-allergic effect of lactic acid bacteria particles in the lactic acid bacteria embedding structure; the storage-resistant layer can enhance the stability of lactic acid bacteria, isolate air, humidity and high temperature, thereby improving the shelf life; the acid and alkali resistant layer is to enhance the resistance of lactic acid bacteria to gastric acid and bile salts, thereby ensuring that the bacteria can smoothly reach and colonize in the intestine; the anti-collision layer can prevent the lactic acid bacteria particles from being compressed and damaged by bacterial powder due to the subsequent processing steps or transportation process, thereby achieving the purpose of improving the survival rate of lactic acid bacteria particles; the present application can enhance the anti-allergic effect of lactic acid bacteria particles through the setting and layout of each layer, and can maintain its activity and improve the shelf life. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] Figure 1 It is a schematic diagram of the structure of this application;

[0013] Figure 2 This is the experimental result 1 of TGF-β of the present application;

[0014] Figure 3 This is the experimental result 2 of TGF-β of the present application;

[0015] Figure 4 This is the experimental result 1 of IFN-γ of the present application;

[0016] Figure 5 This is the experimental result 2 of IFN-γ of this application;

[0017] Figure 6 This is the experimental result 1 of IL-10 of the present application;

[0018] Figure 7 This is the experimental result 2 of IL-10 of the present application;

[0019] Figure 8 This is the experimental result 1 of IL-17 of the present application;

[0020] Fig. 9 This is the experimental result 2 of IL-17 of the present application;

[0021] Fig.10 This is a graph showing the experimental results of OVA-specific IgE antibodies in serum;

[0022] Fig.11 This is a graph showing the experimental results of OVA-specific IgG2a antibodies in serum;

[0023] 110, lactic acid bacteria particles 120, auxiliary functional layer 130, storage resistant layer 140, acid and alkali resistant layer

[0024] 150. Anti-collision layer. DETAILED DESCRIPTION

[0025] The specific implementation of the present invention is described in detail below in conjunction with the accompanying drawings. It should be noted that the specific implementation described here is only used to illustrate and explain the present invention, and is not used to limit the present invention.

[0026] The present embodiment provides a lactic acid bacteria embedding structure with anti-allergic effect, including lactic acid bacteria particles 110, wherein the lactic acid bacteria particles 110 are obtained by centrifugation and concentration after fermentation and culture of lactic acid bacteria with anti-allergic effect; the outer side of the lactic acid bacteria particles is coated with an auxiliary efficacy layer 120, and the auxiliary efficacy layer 120 ensures that after consumption, the lactic acid bacteria particles 110 are coordinated to enhance the anti-allergic effect, thereby enhancing the anti-allergic effect of the lactic acid bacteria particles 110. Preferably, the auxiliary efficacy layer 120 is composed of one of docosahexaenoic acid (DHA), soy peptide, lecithin, yeast extract, β-carotene, and conjugated linoleic acid, or any combination thereof;

[0027] The outer side of the auxiliary functional layer 120 is coated with a storage-resistant layer 130. The storage-resistant layer 130 is used to enhance the stability of the lactic acid bacteria particles 110, isolate air, humidity and high temperature, and thus increase the shelf life. Preferably, the storage-resistant layer 130 is composed of a mixture of one or more of carbohydrates, starches and gums. Most preferably, it is a mixture of carbohydrates, starches and gums. More specifically, the carbohydrates are selected from any one or more substances, including but not limited to: chitosan, seaweed polysaccharides, polysaccharides, fructooligosaccharides, galacto-oligosaccharides, The group consisting of isomalto-oligosaccharide, xylo-oligosaccharide, soybean oligosaccharide, raffinose or any combination thereof; the starch is selected from any one or more substances, including but not limited to: maltodextrin, corn starch, pea starch, potato starch, glutinous rice flour, tapioca starch, wheat starch or any combination thereof; the gum is selected from any one or more substances, including but not limited to: agar, carrageenan, locust bean gum, pectin, alginate, carrageenan, gelatin, guanyin, gum arabic or any combination thereof.

[0028] The outer side of the storage-resistant layer 130 is coated with an acid- and alkali-resistant layer 140. The acid- and alkali-resistant layer 140 is intended to enhance the gastric acid and bile resistance of the lactic acid bacteria particles 110, thereby allowing the bacteria to successfully reach and colonize in the intestine. Preferably, the acid- and alkali-resistant layer 140 is selected from any one or more substances, including but not limited to: corn sugar gum or gum arabic, or a group consisting of any combination of the above.

[0029] The outer side of the acid- and alkali-resistant layer 140 is coated with an anti-collision layer 150, and the anti-collision layer 150 is used to prevent the lactic acid bacteria granules 110 from being compressed and damaged by bacterial powder during the subsequent processing steps or the transportation process, thereby achieving the purpose of improving the survival rate of the lactic acid bacteria granules 110; preferably, the components of the anti-collision layer 140 are selected from any one or several substances, including but not limited to: amylose, microcrystalline cellulose, sorbitol-resistant dextrin, oat fiber, citrus fiber, inulin fiber, colorant, binder, anti-caking agent, anti-foaming agent or any combination of the above.

[0030] Preferably, the lactic acid bacteria particles, the auxiliary functional layer, the storage-resistant layer, the acid-alkali-resistant layer, and the anti-collision layer adopt a triangular structure.

[0031] Embodiment 2:

[0032] The present application provides an experimental method and experimental results of the anti-allergic effect of lactic acid bacteria particles 110 as follows. Specifically, the lactic acid bacteria particles 110 are taken as an example of Lactobacillus paracasei GMNL-133:

[0033] Purpose: To conduct an anti-allergic animal experiment using oral microparticles of Lactobacillus paracasei GMNL-133 to evaluate the anti-allergic ability of GMNL-133.

[0034] Experimental method: The experimental animals of this experiment were BALB / c female mice. On the 0th day of the experiment, 50 μg of ovalbumin (OVA) and adjuvant alum (4 mg) were intraperitoneally injected into the mice. On the 14th and 28th days of the experiment, 25 μg of OVA and 4 mg of alum were repeatedly injected into the mice. Blood was collected from the tails of the mice before and every two weeks after the start of the experiment, and serum was separated for subsequent antibody analysis.

[0035] The mice were divided into a normal group, an OVA-induced disease group, and an OVA-induced disease group plus tube-fed Lactobacillus paracasei GMNL-133 oral microparticles group.

[0036] Preparation and culture of spleen cells: After each group of BALB / c mice was sacrificed by CO2 asphyxiation, the spleen was removed by aseptic operation and placed in a microbial culture dish. 6 ml of PBS was added and the spleen was squeezed and ground with a glass rod to a suspension state. The suspension was slowly added to a 15 ml centrifuge tube that had been filled with 6 ml of Ficoll-Hypaque (17-1400-02, Pharmacia) in advance. Gradient centrifugation was performed to separate spleen cells (720×g, 20 min). The precipitate was red blood cells. The spleen cells were removed from the interface, washed twice with PBS, and the cell concentration was adjusted to 4×10 6 cell / ml, 100μl of spleen cells were injected into each hole of a 96-well plate. The spleen cell culture conditions were divided into three culture methods: no stimulant added (added RPMI 1640 medium), added ConA (culture concentration 10μg / mL) and added OVA (culture concentration 30μg / mL). After 48 hours of culture, the supernatant was collected and the concentrations of various cytokines, such as TGF-β, IFN-γ, IL-10 and IL-17, were detected by ELISA.

[0037] The experimental results of TGF-β are as follows Figure 2 , Figure 3 As shown; the experimental results of IFN-γ are shown Figure 4 , Figure 5 As shown; the experimental results of IL-10 are shown Figure 6 , Figure 7 As shown; the experimental results of IL-17 are shown Figure 8 , Fig. 9 shown.

[0038] ELISA (enzyme immunoassay) was used to measure OVA-specific IgE and IgG2a antibodies in serum: OVA protein (Sigma A5378) was dissolved in sodium bicarbonate buffer solution at pH 9.6 to prepare a solution with a concentration of 10 μg / ml, added to a 96-well plate (200 μl / well), sealed with a film, and placed at 4°C overnight; the next day, each well was rinsed 3 times with ELISA washing buffer (0.05﹪Tween 20 dissolved in PBS), and then 200 μl of blocking buffer (3﹪BSA) was added to each well, and placed at room temperature for 1 hour, and then each well was rinsed 5 times with ELISA washing buffer (0.05﹪Tween 20 dissolved in PBS), and the samples (serum and BALF) were diluted 30 times and added to a 96-well plate (100 μl / well), placed at room temperature for 2 hours, and washed with ELISA washing buffer (washing buffer, 0.05﹪Tween 20 dissolved in PBS). 5. Rinse each well with ELISA washing buffer (0.05﹪Tween 20 dissolved in PBS) for 5 times, add the prepared Biotin-anti-mouse IgE, Biotin-anti-mouse IgG1 or Biotin-anti-mouse IgG2a solution to a 96-well plate (100μl / well), and place at room temperature for 1 hour; then rinse each well with ELISA washing buffer (0.05﹪Tween 20 dissolved in PBS) for 5 times, add TMB substrate to a 96-well plate (100μl / well), and place at room temperature for 30 minutes, and finally add 2N H2SO4 to the 96-well plate (50μl / well), and finally read the absorbance at OD450nm. The final result is expressed as ELISA unit (%) to represent the OVA-specific antibody content in serum:

[0039] ELISA unit (%) = ((Absorb sample -Absorb blank ) / (Absorb placebo -Absorb blank ))x100% serum

[0040] The results of OVA-specific IgE and IgG2a antibodies in Fig.10 , Fig.11 As shown;

[0041] Experimental results: In this experiment, Fig.10As shown in Figure 2, we can observe that the OVA-specific IgE in the serum of BALB / c mice fed with GMNL-133 oral microparticles for five weeks was significantly decreased compared with the Placebo group; in addition, as Fig.11 The OVA-specific IgG2a in the serum of BALB / c mice fed with GMNL-133 for five weeks was significantly increased compared with the Placebo group; Figures 2 to 9 As shown in the figure, after culturing spleen cells of BALB / c mice fed with GMNL-133 for five weeks for 48 hours, the TGF-β, IFN-γ, IL-10 and IL-17 in the cell culture supernatant were detected and it was found that these cytokines were significantly increased compared with the Placebo group. Based on the above experimental results, we can know that the following two points can regulate immunity and alleviate allergic reactions by feeding GMNL-133:

[0042] 1. Lactobacillus paracasei GMNL-133 oral microparticles can stimulate the Th-17 of the body's immune system, thereby shifting the Th1 / Th2 immune response to the Th1 pathway;

[0043] 2. Lactobacillus paracasei GMNL-133 oral microparticles can also stimulate the activation of T regulation cells, thereby inhibiting the immune response of Th2 cells and alleviating allergic reactions.

[0044] In the present application, an auxiliary functional layer is provided to ensure that after consumption, the lactic acid bacteria can cooperate with the lactic acid bacteria to enhance the anti-allergic effect, thereby achieving the effect of improving the anti-allergic effect of the lactic acid bacteria particles in the lactic acid bacteria embedding structure; the storage-resistant layer can enhance the stability of the lactic acid bacteria, isolate air, humidity and high temperature, thereby improving the shelf life; the acid and alkali resistant layer is to enhance the resistance of the lactic acid bacteria to gastric acid and bile salts, thereby ensuring that the bacteria can smoothly reach and colonize in the intestine; the anti-collision layer can prevent the lactic acid bacteria particles from being compressed and damaged by bacterial powder due to the subsequent processing steps or the transportation process, thereby achieving the purpose of improving the survival rate of the lactic acid bacteria particles; the present application can enhance the anti-allergic effect of the lactic acid bacteria particles through the setting and layout of each layer, and can prevent the lactic acid bacteria particles from being compressed and damaged by bacterial powder due to the subsequent processing steps or the transportation process, thereby achieving the purpose of improving the survival rate of the lactic acid bacteria particles, maintaining its activity, improving the shelf life, and thus better achieving the anti-allergic effect.

[0045] The present invention has been described through the above-mentioned relevant embodiments, however, the above-mentioned embodiments are only examples for implementing the present invention; it must be pointed out that the disclosed embodiments do not limit the scope of the present invention. On the contrary, modifications and equivalent settings contained in the spirit and scope of the claims are all included in the scope of the present invention.

Claims

1. A lactic acid bacteria embedding structure with anti-allergic effect, comprising lactic acid bacteria particles (110), characterized in that: The lactic acid bacteria particles (110) are coated with an auxiliary functional layer (120) on the outside, the auxiliary functional layer (120) is coated with a storage-resistant layer (130) on the outside, the storage-resistant layer (130) is coated with an acid- and alkali-resistant layer (140) on the outside, and the acid- and alkali-resistant layer (140) is coated with an anti-collision layer (150) on the outside.

2. The lactic acid bacteria embedding structure with anti-allergic effect according to claim 1, characterized in that: The auxiliary efficacy layer (120) is made of one of docosahexaenoic acid, soybean peptide, lecithin, yeast extract, beta-carotene, and conjugated linoleic acid.

3. The lactic acid bacteria embedding structure with anti-allergic effect according to claim 1, characterized in that: The acid-alkali resistant layer (140) is made of corn gum or gum arabic.

4. The lactic acid bacteria embedding structure with anti-allergic effect according to claim 1, characterized in that: The anti-collision layer (150) is made of one of amylose, microcrystalline cellulose, sorbitol, resistant dextrin, oat fiber, citrus fiber, and inulin fiber.

5. The lactic acid bacteria embedding structure with anti-allergic effect according to claim 1, characterized in that: The lactic acid bacteria particles (110), the auxiliary functional layer (120), the storage-resistant layer (130), the acid-alkali-resistant layer (140), and the anti-collision layer (150) adopt a triangular structure.

Images